Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity, and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity, and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Genetics
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

October 2020; 6 (5) EditorialOpen Access

Genetic risk for Alzheimer disease affects the brain throughout the lifespan

David E.J. Linden
First published September 24, 2020, DOI: https://doi.org/10.1212/NXG.0000000000000516
David E.J. Linden
From the School for Mental Health and Neuroscience, Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences, Maastricht University, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Genetic risk for Alzheimer disease affects the brain throughout the lifespan
David E.J. Linden
Neurol Genet Oct 2020, 6 (5) e516; DOI: 10.1212/NXG.0000000000000516

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
146

Share

  • Article
  • Info & Disclosures
Loading

Neuronal cell death and loss of synapses are hallmarks of the pathology of Alzheimer disease (AD). The incidence of AD increases with age, and both regional and global brain atrophies have been identified as pathological correlates. Thus, AD can, in many respects, be regarded as a paradigmatic neurodegenerative disorder. However, disrupted function of the presenilin genes, the most common cause of early-onset familial AD (FAD), can also affect brain development, including early processes of neuronal migration and morphogenesis.1

Evidence for reduced brain volume has been observed in middle-aged patients with FAD2 and even in infants carrying the apolipoprotein E (APOE) ε4 allele,3 the main common variant associated with late-onset AD (LOAD). Earlier neuropathologic work had identified neurofibrillary changes characteristic of AD in young adults, leading to the speculation that the brain changes associated with AD may precede the clinical syndrome by up to 50 years.4 Converging evidence thus suggests that AD develops through a protracted process of neuropathologic changes that warrants a lifespan perspective.

The identification of additional common risk factors for LOAD and the development of polygenic risk scores summarizing their cumulative effects has further boosted research into the biological mechanisms of AD genetic risk. In this issue of Neurology® Genetics, Walhovd et al.5 investigated the association between AD polygenic risk (including but not confined to the APOE ε4 variant) and hippocampal volume in 1,181 cognitively healthy people (some of whom contributed multiple scans over a time period of several years) with a wide age range (4–95 years). They confirmed the reduction in hippocampal volume found earlier in a sample of young adults6 and, importantly, demonstrated that it was fairly consistent across age groups. The absence of strong interaction effects with age would suggest that AD polygenic risk mainly leads to an earlier onset of brain ageing (and loss of cognitive reserve) rather than an accelerated ageing process, although more longitudinal data would be needed to confirm this interpretation. What is also interesting about these findings is that, as the authors rightly point out, they are at odds with an antagonistic pleiotropy account of ageing, which posits that genetic variants that are detrimental in later life have a positive effect on fitness earlier in life to remain in the gene pool of a species. At least regarding the brain phenotype of hippocampal volume, there was no evidence of a beneficial effect of AD-related genes earlier in life.

What, then, are the clinical implications of the identification of brain correlates of genetic AD risk across the lifespan? One of the key approaches in the development and evaluation of new treatments is based on the early identification of prospective patients before the onset of clinically manifest symptoms. The biomarkers developed so far have limited clinical utility for AD prediction7 and thus new multimodal approaches, incorporating both genetic risk scores and parameters of neural structure and function, should be welcome. The lifespan focus of the study by Walhovd et al. is particularly useful in this respect. Modifiable risk factors for AD build up over years,8 and recent epidemiologic studies have highlighted the importance of dementia prevention in early life, for example, through the enhancement of cognitive reserve.7 Although we are still far away from any use of hippocampal volume as a clinical proxy for cognitive reserve, the study by Walhovd et al. makes a compelling case for further longitudinal research into links between AD risk and brain structure.

Study funding

No targeted funding reported.

Disclosure

No relevant disclosures. Go to Neurology.org/NG for full disclosures.

Footnotes

  • Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.

  • See page e506

  • Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work, provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Louvi A,
    2. Sisodia SS,
    3. Grove EA
    , Presenilin 1 in migration and morphogenesis in the central nervous system. Development 2004;131, 3093–3105.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Cash DM,
    2. Ridgway GR,
    3. Liang Y, et al
    . The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. Neurology 2013;81:1425–1433.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Dean DC,
    2. Jerskey B,
    3. Chen K, et al
    . Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol 2014;71, 11–22.
    OpenUrl
  4. 4.↵
    1. Braak H,
    2. Braak E
    , Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995;16:271–278.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Walhovd KB,
    2. Fjell AM,
    3. Sørensen Ø, et al
    . Genetic risk for Alzheimer's disease predicts hippocampal volume through the human lifespan. Neurol Genet 2020;6:e506.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Foley SF,
    2. Tansey KE,
    3. Caseras X, et al.
    , Multimodal brain imaging reveals structural differences in alzheimer's disease polygenic risk carriers: a study in healthy young adults. Biol Psychiatry 2017;81:154–161.
    OpenUrlCrossRef
  7. 7.↵
    1. Livingston G,
    2. Huntley J,
    3. Sommerlad A, et al
    . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396:413–446.
    OpenUrl
  8. 8.↵
    1. Vos SJB,
    2. van Boxtel MPJ,
    3. Schiepers OJG, et al
    . Modifiable risk factors for prevention of dementia in midlife, late life and the oldest-old: validation of the LIBRA index. J Alzheimers Dis 2017;58:537–547.
    OpenUrl
View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Study funding
    • Disclosure
    • Footnotes
    • References
  • Info & Disclosures

Related Articles

  • Genetic risk for Alzheimer disease predicts hippocampal volume through the human lifespan

Topics Discussed

  • All Genetics
  • Alzheimer's disease
  • MRI

Alert Me

  • Alert me when eletters are published
Advertisement
Neurology Genetics: 7 (1)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Genetics | Online ISSN: 2376-7839

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise